Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2005-09-13
2005-09-13
Mosher, Mary E. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C424S232100, C435S320100, C435S235100
Reexamination Certificate
active
06942864
ABSTRACT:
The present invention is directed to the use of a live, recombinant leporipox virus comprising exogenous DNA, which is operably linked to at least one expression control element and which is incorporated in a non-essential region of the virus genome, in the manufacture of a vector vaccine for the treatment and/or prophylaxis of infectious diseases in non-lepori species. The invention furthermore relates to a live, recombinant leporipox virus comprising exogenous DNA operably linked to at least one expression control element and incorporated in a non-essential region of the virus genome characterized in that said exogenous DNA encodes at least one antigen of a non-lepori pathogen. Due to its restricted host-range the recombinant leporipox virus is non-pathogenic in non-susceptible hosts such as non-lepori vertebrates. Vaccination with said recombinant leporipox virus induced an antigen or immunogenic response in the vaccinated non-lepori host even though productive replication of the virus was not observed in the host.
REFERENCES:
patent: 5174993 (1992-12-01), Paoletti
patent: 5505941 (1996-04-01), Paoletti
patent: 5942235 (1999-08-01), Paoletti
patent: 6001349 (1999-12-01), Panicali et al.
patent: 6127172 (2000-10-01), Moyer et al.
patent: 6294176 (2001-09-01), Cochran et al.
patent: 6338962 (2002-01-01), Boyce
patent: 6340462 (2002-01-01), Paoletti
patent: 0 652 287 (1995-05-01), None
patent: 0 652 287 (1995-05-01), None
patent: 0 972 840 (2000-01-01), None
patent: 0972840 (2000-01-01), None
patent: 2 736 358 (1997-01-01), None
patent: WO 89/03429 (1989-04-01), None
patent: WO 93/01284 (1993-01-01), None
patent: WO 99/61069 (1999-12-01), None
Tartaglia et al (Journal of Virology 67:2370-2375, 1993).
Pastoret, P.P. et al, Dev. Biol. Stand. Basel, Karger, V84 p183-193, (1995): Target and Non-Target Effects of a Recombinant Vaccinia-Rabies Virus Developed for Fox . . .
Paoletti, E. et al, Dev. Biol. Stand., Basel, Karger, V82 p65-69, (1994): Safe and Effective Poxvirus Vectors-NYVAC and ALVAC.
Perkus, M.E., et al, Ann.N.Y. Acad. Sci., V75, p222-233 (May 1995): Live Attenuated Vaccinia and Other Poxviruses as Delivery Systems: Public Health Issues.
Messud-Petit, F., Virologie, V4, N6, p453-462, (Nov.-Dec. 2000) “Le virus myxomateux: de l'agent pathogene au vecteur vaccinal”.
Jackson, R.J., et al, J. of General Virology V73, p3241-3245 (1992): “A myxoma virus intergenic transient dominant selection vector”.
Holland, M.K., et al, Reprod. Fertil. Dev., 6(5), p631-642, (1994): Virus-vectored Immunocontraception for Control of Wild Rabbits: Identification of Target Antigens . . .
Jackson, R. J., et al, J. Gen. Virol., V77, p1569-1575, (1996): Construction of recombinant myxoma viruses expressing foreign genes from different intergenic sites without . . .
Tyndale-Biscoe, C.H., Reprod. Fertil. Deve. V6, p281-287 (1994) Virus-vectored Immunocontraception of Feral Mammals.
Robinson, A.J., et al, 1995 Joint Conference AAZV/WDA/AAWV: Recombinant myxoma viruses containing reproductive tract antigents: can they be used to control wild rabbit in . . .
Hu, Liangbiao et al (Cornell Universtiy, Ph.D., DAI V55(11), SECB, p4746) (Jan. 1995): Development of raccoon poxvirus-vectored feline recombinant vaccines.
Fischer, L. et al., Vaccine, V15 N1, p90-96 (1997): A recombiant canarypox virus protects rabbits against a lethal rabbit hemorrhagic disease virus (RHDV) challenge.
Kerr, P. et al., Vaccine, V13, N17, p1722-1726 (1995): Myxoma virus as a vaccine vector for rabbits: antibody levels to influenza virus haemagglutinin presented by a . . .
Opgenorth, A., et al., J. Virology, V66, N8, p 4720-4731 (Aug. 1992): Deletion Analysis of Two Tandemly Arranged Virulence Genes in Myxoma Virus, M11L and Myxoma Growth . . .
Hu, Liangbiao, et al., Vaccine, V15, N12/13, p1466-1472 (1997): Raccoon poxvirus live recombinant feline panleukopenia virus VP2 and rabies virus glycoprotein bivalent . . .
Taylor, J., et al., Vaccine, V15, N12/13, p539-549 (1995): Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species.
Pincus, S., et al., Biologicals V23, p159-164 (Jun. 1995): Poxvirus-Based Vectors as Vaccine Candidates.
Bertagnoli, S., et al., Vaccine, V14, N6, p506-510 (1996): Protection of rabbits against rabbit viral haemorrhagic disease with a vaccinia-RHDV recombinant virus.
Paoletti, E., Proc. Natl. Acad. Sci. USA V93, p11349-11353 (Oct. 1996): Applications of pox virus vectors to vaccination: An update.
Rodriguez, D., et al., Proc. Natl. Acad. Sci. USA V86, p1287-1291 (Feb. 1989): Highly attenuated vaccina virus mutants for the generation of safe recombinant viruses.
Perkus, M., et al., J. of Virology, V63, N9, p3829-3836 (Sep. 1989): Cloning and Expression of Foreign Genes in Vaccinia Virus, Using a Host Range Selection System.
Welter, J. et al., Vaccine, V17 p308-318, (1999) Mucosal vaccination with recombinant poxvirus vaccines protects ferrets against symptomatic CDV infection.
Taylor, J. Prog.vet Microbiol. Immun. V4, p197-217 (1998): Pox viruses as eukaryotic cloning and expression vectors: future medical and veterinary vaccines.
Taylor, J. et al., Vaccine, V6 p 497-503 (Dec. 1998): Recombinant fowlpox virus inducing protective immunity in non-avaian species.
Taylor, J. et al., Vaccine, V 6 p466-468 (Dec. 1998): Fowlpox virus as a vector in non-avian species.
Dallo, S., et al., Virology, V173, p323-329 (1989): Humoral Immune Response Elicited by Highly Attenuated Variants of Variants Virus and by an Attenuated Recombinant . . .
Tartaglia J et al: “Protection of Cats Against Feline Leukemia Virus by Vaccination with a Canarypox Virus Recombinant, ALVAC-FL”; Journal of Virology, New York, US, US, vol. 67, No. 4, Apr. 1993; pp. 2370-2375.
Barcena J. et al: “Horizontal Transmission Protection Against Myxomatosis and Rabbit Hemorrhagic Disease by Using a Recombinant Myxoma Virus”; J. Virology, vol. 74, No. 3, Feb. 2000; pp. 1114-1123.
Paoletti Enzo: “Applications of Pox Virus Vectors to Vaccination: An Update”; Proceedings of the National Academy of Sciences of USA, US, National Academy of Science, Washington; vol. 93, No. 21; Oct. 1996.
Akzo Nobel N.V.
Milstead Mark W.
Mosher Mary E.
LandOfFree
Leporipox-based vector vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Leporipox-based vector vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Leporipox-based vector vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3387619